Cargando…

Will avilamycin convert ziracine into zerocine?

Detalles Bibliográficos
Autor principal:	Shryock, T R
Formato:	Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2001
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631777/ https://www.ncbi.nlm.nih.gov/pubmed/11384546

Ejemplares similares

Will avilamycin convert ziracine into zerocine?
por: Courvalin, P
Publicado: (2000)

Draft Genome Sequence of Streptomyces viridochromogenes Strain Tü57, Producer of Avilamycin
por: Grüning, Björn A., et al.
Publicado: (2013)

Optimal Regimens and Clinical Breakpoint of Avilamycin Against Clostridium perfringens in Swine Based on PK-PD Study
por: Huang, Anxiong, et al.
Publicado: (2022)

Complete Genome Sequences of Two Avilamycin-Resistant Enterococcus faecium Strains Isolated from Chicken in the United States
por: Zhao, S., et al.
Publicado: (2019)

Research Note: Snapshot of the transcriptome via RNA sequencing in the ileum of broiler chickens fed subtherapeutic concentrations of avilamycin
por: Fibi-Smetana, Silvia, et al.
Publicado: (2020)

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

Salud y eficiencia /
por: Shryock, Harold
Publicado: (1965)

The methods and materials of demography /
por: Shryock, Henry S.
Publicado: (1976)

Icatibant as an early rescue therapy in hypovolemic shock with converting enzyme inhibitor treatment
por: Charbonneau, Hélène, et al.
Publicado: (2017)

Glycemic Control Was Unchanged in Veterans Health Administration Patients Converted from Glyburide to Glipizide
por: Aspinall, Sherrie L., et al.
Publicado: (2012)

The Advent of Modern Medicine in Philadelphia, 1800-1850
por: Shryock, Richard H.
Publicado: (1941)

Public Relations of the Medical Profession in Great Britain and the United States: 1600-1870: A Chapter in the Social History of Medicine
por: Shryock, Richard H.
Publicado: (1930)

The Origins and Significance of the Public Health Movement in the United States
por: Shryock, Richard H.
Publicado: (1929)

Angiotensin converting enzyme gene polymorphism in type 2 diabetics with nephropathy
por: Naresh, V. V. S., et al.
Publicado: (2010)

Angiotensin converting enzyme gene polymorphism and influence of ACE inhibition
por: Arman, Q.
Publicado: (2010)

Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing link
por: Van den Eynde, Jef, et al.
Publicado: (2021)

Icatibant, another piece of the therapeutic puzzle regarding hemodynamic side effects of angiotensin-converting enzyme inhibitors
por: Honore, Patrick M., et al.
Publicado: (2019)

An Ultra-Wide Load Range Voltage Converter Using Proactive Phase Frequency Modulation for IoT Sensors
por: Arslan, Saad, et al.
Publicado: (2020)

Sense of Belonging, Religious Activity, and Well-Being in Long-Term Care Residents
por: Shryock, Kelly, et al.
Publicado: (2020)

Renin Angiotensin Converting Enzyme 2 and COVID-19: Prevention and Treatment
por: Kafami, Marzieh, et al.
Publicado: (2021)

COVID-19 and angiotensin-converting enzyme inhibitors from plant origin
por: Gharebaghi, Reza, et al.
Publicado: (2022)

A converted spray device for topical pharyngeal anesthesia in awake intubation
por: Li, Xue, et al.
Publicado: (2021)

Converting disability to opportunity: GDM women as new role models of diabetes care
por: Gupta, Yashdeep, et al.
Publicado: (2014)

Determinants of circulating angiotensin-converting enzyme 2 protein levels in the general population
por: Kuznetsova, Tatiana, et al.
Publicado: (2021)

Another perspective for COVID-19 pandemic: Angiotensin-converting enzyme 2 and ethnicity
por: Simsek, Feride Irem, et al.
Publicado: (2020)

Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors
por: Bots, Sophie H., et al.
Publicado: (2022)

His345 mutant of angiotensin-converting enzyme 2 (ACE2) remains enzymatically active against angiotensin II
por: Liu, Pan, et al.
Publicado: (2021)

Role of angiotensin-converting enzyme in myeloid cell immune responses
por: Cao, Duo-Yao, et al.
Publicado: (2020)

The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?
por: Essig, Marie, et al.
Publicado: (2020)

Effectiveness of C1-INH therapy in angiotensin converting enzyme inhibitor induced angioedema
por: Kovaltchouk, Uliana, et al.
Publicado: (2021)

Reply to “Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing link”
por: Elgendy, Islam Y., et al.
Publicado: (2021)

Angiotensin-Converting Enzyme 2 as the Molecular Bridge Between Epidemiologic and Clinical Features of COVID-19
por: Bombardini, Tonino, et al.
Publicado: (2020)

An observed association between angiotensin-converting enzyme 2 polymorphisms and COVID-19 severity in China
por: Wang, Jin, et al.
Publicado: (2022)

Power converters: definitions, classification and converter topologies
por: Bordry, Frederick
Publicado: (2006)

Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score
por: Vavougios, George D.
Publicado: (2020)

Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
por: Rossato, Marco, et al.
Publicado: (2020)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blocker in coronavirus disease 2019: Safe and possibly beneficial
por: Gupta, Nitesh, et al.
Publicado: (2020)

Angiotensin-converting enzyme G2350A gene polymorphisms and hypertension among patients with intracerebral hemorrhage
por: Joob, Beuy, et al.
Publicado: (2019)

No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

To do or not to do: Angiotensin converting enzyme inhibitors/angiotensin receptor blocker in COVID-19 elderly patients
por: Vura, Naga Venkata Rama Krishna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hi8t4nem3mt0jntoqmptts9u1m